

ACCELERATE Multistakeholder Paediatric Platform

# 5<sup>th</sup> Annual Paediatric Oncology Conference



SAVE THE DATE

2-3 March 2017 | Brussels, Belgium





# Multistakeholder Paediatric Oncology Platform

## To improve new oncology drug development for children

December 2013



Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer

[Eur J Cancer 2015;51:218.](#)



Gilles Vassal<sup>a,\*</sup>, Raphaël Rousseau<sup>b</sup>, Patricia Blanc<sup>c</sup>, Lucas Moreno<sup>d</sup>, Gerlind Bode<sup>e</sup>, Stefan Schwoch<sup>f</sup>, Martin Schrappe<sup>g</sup>, Jeffrey Skolnik<sup>h</sup>, Lothar Bergman<sup>i</sup>, Mary Brigid Bradley-Garelik<sup>j</sup>, Vaskar Saha<sup>k</sup>, Andy Pearson<sup>l</sup>, Heinz Zwierzina<sup>m</sup>

Academia, Industry, Parents, Regulatory Bodies

## 5 objectives to improve new oncology drug development for children and adolescents

1. Pediatric development should be based on drug **mechanism of action** instead of adult indication
2. **Prioritisation** should be set up to choose compounds to be evaluated or not in children
  - Based on MOA, needs, feasibility
  - Using stonger biological and preclinical data
3. **Reduce delays in starting pediatric development**

# Achievements 2016


✓ **iMATRIX Trial Concept** Genentech   
*Match Promising Molecules to Pediatric Patients with High Unmet Needs* Launched in 2016

✓ **e★smart** **AcSé** **ITCC** Launched in August 2016  
 European proof of concept therapeutic stratification trial of molecular anomalies in relapsed or refractory tumors in children  
 INSTITUT NATIONAL DU CANCER  
 Innovative Therapies for Children with Cancer  
 European Consortium

As part of the ITCC Precision Medicine Strategy

✓ **NCI-COG Pediatric MATCH Study** Ready to be Launched  
*(Molecular Analysis for Therapy Choice)*

✓ **ITCC-P4** Ready to be Launched



**Pediatric Preclinical POC Platform/ Public Private Partnership**

The diagram shows a six-step process flow: 1. Target Actionability Reviews (microscope icon), 2. In Silico Target Patterns (DNA helix icon), 3. Preclinical Model Development (10 Diseases, 400 PDX, >20 GEMM), 4. Molecule POC Testing (DNA helix icon), 5. Data Reporting & Molecule Determinations (microscope icon), 6. Regulatory Preclin Consensus (microscope icon).

# Achievements 2016



- ✓ . **The first Paediatric Strategy Forum**

## 5 objectives to improve new oncology drug development for children and adolescents

1. Pediatric development should be based on drug **mechanism of action** instead of adult indication
2. **Prioritisation** should be set up to choose compounds to be evaluated or not in children
  - Based on MOA, needs, feasibility
  - Using stonger biological and preclinical data
3. **Reduce delays in starting pediatric development**
4. **Break the 18 years dogma**
5. **New incentives and rewards**

## How to accelerate?

1. More science
2. More and prioritized innovative compounds
3. Without any delay
4. For more children and adolescents
5. To be introduced early in treatments
6. More investments
7. More effective incentives

**Need for a better regulatory environment  
And increased cooperation between stakeholders**